Skip to content

QLB and Radical Cystectomy, Postoperative Pain

Comparing Two Different Analgesic Block Methods for Postoperative Pain and Recovery After Surgery -Quadratus Lumborum Block (QLB): the Effect on Peri- and Postoperative Pain and Recovery After Radical Cystectomy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03328988
Acronym
BladderQLB
Enrollment
41
Registered
2017-11-01
Start date
2017-04-27
Completion date
2021-08-31
Last updated
2022-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain, Chronic Pain Post-Proceduraal, Nausea and Vomiting, Postoperative

Keywords

bladder cancer, radical cystectomy, epidural analgesia, quadratus lumborum block, postoperative pain

Brief summary

There are ca 1000 new cases of bladder cancer in Finland/year. The curative therapy for high risk bladder cancer is radical cystectomy. The golden standard is still an open surgery despite development of laparoscopic techniques. Epidural analgesia is considered as most effective for the treatment of postoperative pain. However, there is a need for other effective options, because epidural analgesia has some contraindications and risks for serious complications. Recently quadratus lumborum block has gained popularity in the treatment of postoperative pain after various surgeries in the area from hip to mamilla. It is more beneficial than other peripheral blocks, since it covers also the visceral nerves. Contrary to the need of epidural catether a single shot QLB has reported to last up to 48 hours. Inadequately treated acute postoperative pain is considered as one of the main risk factors for persistent postoperative pain. 44 patients aging 18-85 will be recruited based on a power calculation. The primary outcome measure is the acute postoperative need for rescue analgesics. Secondary outcomes are acute pain (NRS scale), nausea, vomiting, mobilisation and longterm outcomes such as quality of life and persistent pain.

Detailed description

44 patients, uindergoing radical cystectomy, aging 18-85 will be recruited based on a power calculation. The 44 patients will be divided in 2 groups, the intervention group receiving a quadratus lumborum block (75mg ropivacaine) and the no intervention group receiving the current standard care of our hospital -an epidural. The primary outcome measure is the acute postoperative need for rescue analgesics. Secondary outcomes are acute pain (NRS scale), nausea, vomiting, mobilisation and longterm outcomes such as quality of life and persistent pain.

Interventions

PROCEDUREQLB

bilateral single shot block, placed under ultrasound control between the thoracolumbar fascial structures close to the quadratus lumborum muscle

Sponsors

Tampere University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Masking description

Patients are randomized and allocated in blocks of ten to either epidural of QLB group

Intervention model description

Prospective randomized controlled study

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* patients with bladder cancer coming to the open radical cystectomy.

Exclusion criteria

* age under 18y or over 85y, * diabetes type 1 with complications, * no co-operation or inadequate finnish language, * persistent pain for other reason.

Design outcomes

Primary

MeasureTime frameDescription
opiate consumption24 hoursintravenous patient controlled analgesia

Secondary

MeasureTime frameDescription
postoperative nausea and vomiting72 hoursnumerical rating scale and amount of vomites
mobilisation72 hours after surgerystanding up and mobilizing
pain score7 daysnumerical rating scale
persistent pain12 monthspaindetect McGill
functional query12 monthsassessment how pain in operation region limits daily functions
quality of life12 monthsSF 36

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026